SCHEMBL5340805

SCHEMBL5340805

CC(C)(C)OC(=O)N1CCN(c2ccccc2Cn2ncnn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.46
SMARCA4 P51532 1/20 0.46
PBRM1 Q86U86 1/20 0.46
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
KIT P10721 1/20 0.44
BACE1 P56817 2/20 0.44
ACHE P22303 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
PLA2G7 Q13093 1/20 0.43
MGLL Q99685 1/20 0.43
ABHD6 Q9BV23 1/20 0.43
KDM1A O60341 4/20 0.42
TP53 P04637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7981893 0.81 GAA (0.56) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL5336529 0.80 MC4R (0.54) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL5335100 0.79 PLA2G7 (0.61) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL615074 0.79 CHRM2 (0.52) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL5335298 0.78 MGLL (0.60) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL416461 0.78 ACHE (0.51) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL4511470 0.78 GPR119 (0.50) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL110163 0.78 NCF1 (0.51) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL28708137 0.78 GPR119 (0.49) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL28447724 0.77 MGLL (0.68) CKS1BSKP1SKP2CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R SMARCA2 4437/4885SMARCA4 4290/4885PBRM1 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.